Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude

This partnership signals growing adoption of large language models like Claude in specialized, high-stakes industries such as pharmaceuticals, moving AI beyond consumer chatbots into scientific R&D. For consumers, faster and more efficient drug discovery could eventually mean quicker access to new treatments, while for the tech industry it underscores AI companies' push to prove enterprise value in complex domains.

• Novo and Anthropic are collaborating to apply Claude to drug-discovery workflows.
• The goal is to address specific bottlenecks in the drug-discovery process through tailored AI solutions.
• The deal reflects a broader trend of AI firms expanding into specialized scientific and industrial applications.